Condition

Myeloma clinical trials and research

• 21Clinical trials
• 167NIH research projects
• 8Countries

Newest Myeloma clinical trials

All recruiting trials (21)

• Genetics of Blood Cancers in the U.S. population

  This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.

  Recruiting Rutgers, The State University of New Jersey · Piscataway, New Jersey · NCT07714044

• Remote rehabilitation for people receiving CAR-T cell therapy

  This project will test a home-based telerehabilitation program using interactive exercise, nutrition, behavioral support, and remote monitoring for people with lymphoma or myeloma who are getting CAR-T therapy.

  Recruiting University of Utah · Salt Lake City, Utah · NCT07390071

• Stopping immunoglobulin replacement with or without antibiotics to prevent infections in blood cancer patients

  This trial tests if stopping immunoglobulin replacement, with or without daily preventive antibiotics, is safe and keeps infections low in people with myeloma, leukemia, or non-Hodgkin's lymphoma who have been on Ig therapy.

  Recruiting at 3 sites Phase 2/3 Monash University · Adelaide, South Australia and 2 other locations · NCT07202091

• Preventing infections in people with blood cancers using antibiotics or immunoglobulin

  This project tests whether giving regular intravenous immunoglobulin or prophylactic antibiotics better prevents infections in people with myeloma, non-Hodgkin lymphoma, or leukemia who have not yet started immunoglobulin replacement.

  Recruiting at 3 sites Phase 2/3 Monash University · Adelaide, South Australia and 2 other locations · NCT07202078

• Antibiotics versus immunoglobulin to prevent infections in people with blood cancers

  This trial tests whether taking preventive antibiotics instead of regular IV immunoglobulin can prevent infections in people with myeloma, non-Hodgkin lymphoma, or leukemia.

  Recruiting at 3 sites Phase 2/3 Monash University · Adelaide, South Australia and 2 other locations · NCT07202065

• Comparing antibiotics and immunoglobulin to prevent infections in blood cancers

  This project tests whether immunoglobulin or antibiotic strategies better prevent infections in adults with blood cancers.

  Recruiting at 3 sites Phase 2/3 Monash University · Adelaide, South Australia and 2 other locations · NCT07202052

• Siltuximab treatment for CRS and ICANS after CAR‑T in multiple myeloma

  We will test whether siltuximab helps adults with multiple myeloma who develop CRS or ICANS after receiving CAR‑T therapy.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07106671

• Telehealth music therapy for cognitive difficulties in blood cancer survivors

  This program will test whether telehealth music therapy can help adults who survived leukemia, lymphoma, or myeloma and who are having trouble with memory, attention, or thinking.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07052916

• Skin tests to check biotherapy allergies in cancer patients

  We are testing skin tests to see if cancer patients treated with biotherapies have allergies or hypersensitivity to those drugs.

  Recruiting University Hospital, Angers · Angers · NCT06971848

• Elranatamab treatment after cilta-cel for high-risk relapsed myeloma patients

  This study is testing if Elranatamab can help high-risk myeloma patients who have already had cilta-cel live longer without their disease getting worse.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06947083

• Combining Elotuzumab and Iberdomide with Dexamethasone for Relapsed Multiple Myeloma

  This study is testing a new combination of Elotuzumab, Iberdomide, and Dexamethasone to see if it helps people with relapsed multiple myeloma who have already tried another treatment.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT06518551

• Home blood transfusions for people with advanced blood cancers in hospice

  The study will test whether offering home blood transfusions to adults with advanced or relapsed blood cancers who are eligible for hospice helps improve quality of life, mood, and end-of-life care.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06487247

• Prophylactic use of Tocilizumab to prevent complications after CAR-T therapy

  This study is testing if giving Tocilizumab before or during CAR-T therapy can help prevent serious side effects like cytokine release syndrome and neurotoxicity in patients with B-cell cancers.

  Recruiting Phase 2 Insel Gruppe AG, University Hospital Bern · Bern, Canton of Bern · NCT06430736

• Platform for Rare Blood Disorders in Europe

  This study is trying to gather and share information about rare blood disorders across Europe to help researchers understand these conditions better and improve treatment options for patients.

  Recruiting Hospital Universitari Vall d'Hebron Research Institute · Barcelona, Catalonia · NCT06250595

• Impact of Leukemia and Lymphoma Society services on blood cancer patients

  This study is testing how the services provided by the Leukemia and Lymphoma Society can help people with blood cancers feel better and manage their care over six months.

  Recruiting University of Miami · Miami, Florida and 2 other locations · NCT05745285

• Testing a new drug for patients with advanced multiple myeloma

  This study is testing a new drug called KTX-1001 to see if it is safe and effective for adults with advanced multiple myeloma who have not responded to other treatments.

  Recruiting at 26 sites Phase 1 K36 Therapeutics, Inc. · San Francisco, California and 28 other locations · NCT05651932

• Using Belantamab Mafodotin to treat high-risk smoldering multiple myeloma

  This study is testing a new treatment called Belantamab Mafodotin to see if it is safe and effective for people with high-risk smoldering multiple myeloma.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT05055063

• Fecal Microbiota Transplantation to Prevent Complications After Stem Cell Transplantation

  This study is testing whether giving a special stool treatment can help prevent complications like Graft-versus-Host Disease in patients receiving stem cell transplants for blood cancers.

  Recruiting at 3 sites Phase 2 University Hospital, Clermont-Ferrand · Amiens and 19 other locations · NCT04935684

• Developing a liquid biopsy protocol for cancer research at Princess Margaret

  This study is trying to create a simple way to collect blood samples from cancer patients to see if analyzing certain molecules in their blood can help doctors understand their cancer better and track how it changes over time.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT03702309

• Imaging study to evaluate leukemia treatment response

  This study is testing if a special type of imaging can help doctors see how well treatments are working for people with high-risk acute leukemia or myeloma.

  Recruiting Phase 1 University of Oklahoma · Washington D.C., District of Columbia and 2 other locations · NCT03633955

• Registry for patients with lymphoid cancers

  This study is collecting information from patients with Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma to better understand their conditions and improve treatment options.

  Recruiting A.O. Ospedale Papa Giovanni XXIII · Bergamo · NCT03131531

NIH-funded research (newest 40 of 167)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Integrative study of multiple myeloma genetics and disease biology

  A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11535381

• Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma

  A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.

  NIH research Washington University · Saint Louis, United States · NIH-11495288

• How LDL Affects Multiple Myeloma: New Pathways to Keep Remission

  A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.

  NIH research Univ of Arkansas for Med Scis · Little Rock, United States · NIH-11444783

• Therapy-induced senescence and immune activation in multiple myeloma

  A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11433329

• BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma

  A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11433305

• Understanding Drug-Resistant Multiple Myeloma to Stop Relapse

  Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.

  NIH research Central Arkansas Veterans Hlthcare Sys · North Little Rock, United States · NIH-11428791

• Overcoming resistance to CART cell therapy in multiple myeloma

  This grant aims to improve CAR T-cell therapy for people with multiple myeloma by tackling why some patients stop responding, using innovative approaches to boost cancer-fighting cells in the bone marrow.

  NIH research Mayo Clinic Arizona · Scottsdale, United States · NIH-11421175

• In vivo CAR-T for myeloma: a new approach to make CAR-T inside patients

  A Mayo Clinic Arizona team is testing a one-step therapy that could turn a patient’s own T cells into anti-myeloma CAR-T cells inside the body, aiming to make CAR-T treatment more accessible.

  NIH research Mayo Clinic Arizona · Scottsdale, United States · NIH-11421172

• Mayo Clinic Mayo Myeloma SPORE Renewal 2025

  A Mayo Clinic research program is renewing a translational effort to advance personalized approaches for multiple myeloma that could benefit patients at Mayo sites and beyond.

  NIH research Mayo Clinic Arizona · Scottsdale, United States · NIH-11421168

• Engineering Better T Cell Therapy for Multiple Myeloma

  A patient-focused program to improve CAR-T cell therapy for multiple myeloma by making T cells more sensitive and able to target multiple cancer markers.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11420374

• Targeting the BiP protein to trigger cancer cell death in multiple myeloma

  A physician-scientist in training is studying how a key cellular stress pathway keeps plasma cells alive in multiple myeloma and exploring BiP as a potential therapeutic target.

  NIH research Indiana University Indianapolis · Indianapolis, United States · NIH-11418985

• CTO1681: reducing dangerous immune reactions in patients getting CAR T-cell therapy

  A new oral drug (CTO1681) aims to prevent and lessen cytokine release syndrome in patients with blood cancers treated with CAR T-cell therapy.

  NIH research Cytoagents, INC. · Pittsburgh, United States · NIH-11418976

• Differences in tumor biology of multiple myeloma across ancestries

  This NIH grant studies why multiple myeloma affects people with African ancestry differently by comparing tumor genetics and the tumor environment between patients of African and European ancestry.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11415779

• Improving durability of responses after CAR T therapy for myeloma

  This grant explores new CAR T cell approaches to keep multiple myeloma patients in remission longer after initial treatment success.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11413794

• Bone marrow pH and multiple myeloma progression in veterans

  This project looks at how the acidity inside bone marrow affects how multiple myeloma behaves and responds to treatment in veterans.

  NIH research VA Greater Los Angeles Healthcare System · Los Angeles, United States · NIH-11412885

• In vivo BCMA-CAR T therapy delivered by a single IV treatment for multiple myeloma

  A new therapy aims to generate CAR-T cells directly inside the patient’s body to treat multiple myeloma, potentially reducing wait times and procedure costs.

  NIH research Vyriad, INC. · Rochester, United States · NIH-11410209

• Detection and isolation of circulating myeloma cells for a minimally invasive blood test

  A new blood-based test aims to detect and isolate rare myeloma cells from a simple blood draw to help monitor and guide treatment.

  NIH research Cellsbin, INC. · Branford, UNITED STATES · NIH-11409627

• Enhancing BCMA CAR T cells to achieve lasting responses in multiple myeloma

  Aimed at making BCMA CAR T cell therapy work better for people with multiple myeloma by improving how well the engineered cells recognize and attack cancer cells.

  NIH research Sollus Therapeutics, INC. · Chapel Hill, United States · NIH-11407469

• Targeting DNA instability and evolution in myeloma

  A research program at Dana-Farber Cancer Institute studies how genetic instability drives multiple myeloma to evolve and resist treatment, with a focus on DNA repair pathways.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11403930

• Understanding how lncRNAs affect multiple myeloma biology and treatment

  This grant studies how long noncoding RNAs influence multiple myeloma behavior and response to therapy using bone marrow models.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11403925

• Understanding how cancer drugs affect transcriptional hubs in multiple myeloma

  A research team is studying how cancer cells in multiple myeloma regulate gene activity and how drugs interact with those gene-control hubs to possibly improve treatments.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11403922

• MRD-guided quadruplet therapy and autologous stem cell transplant in newly diagnosed multiple myeloma

  This study asks if using a highly targeted blood cancer treatment plan and a stem cell transplant can deepen responses and improve outcomes for people with newly diagnosed multiple myeloma.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11403916

• Integrative Oncogenomics of Multiple Myeloma (MM)

  A translational research program at Dana-Farber brings together basic biology, clinical science, and genomic data to better understand and treat multiple myeloma.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11403915

• Molecular clues to when multiple myeloma starts in at-risk people

  This grant focuses on finding early signs that multiple myeloma begins in people at higher risk, especially older Black individuals, so we might catch the disease before it causes serious problems.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11401406

• Molecular clues to predict myeloma risk in Black adults

  Researchers are looking for genomic signs that could predict who among Black adults ages 50+ will develop multiple myeloma, aiming to catch the disease early.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11401388

• Survivorship in Multiple Myeloma Patients Treated with CAR T-Cell Therapy

  This study looks at real-world experiences and well-being of people with multiple myeloma who received CAR T-cell therapy, focusing on their symptoms, mood, and quality of life.

  NIH research H. Lee Moffitt Cancer Ctr & Res Inst · Tampa, United States · NIH-11400064

• Immunoprevention for multiple myeloma using preclinical models

  Researchers will study early-stage multiple myeloma using mouse models to test safe, low-risk prevention strategies for people at high risk of progression.

  NIH research Mayo Clinic Arizona · Scottsdale, United States · NIH-11399807

• Understanding how CD56 helps multiple myeloma grow and hide from the immune system

  A research program to learn why a protein called CD56 helps multiple myeloma progress and avoid immune attack, with the goal of developing new ways to slow or stop the disease.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11395223

• Understanding gene-regulating condensates in multiple myeloma

  This project looks at how small clumps of gene-regulating molecules affect multiple myeloma cells to point toward new treatment ideas for people with the disease.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11389122

• Understanding multiple myeloma genetics and treatment outcomes

  This program looks at how genetic and molecular features of multiple myeloma relate to patient outcomes and whether high‑dose therapy helps people who become minimal residual disease (MRD) negative.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11387058

• Morning light to improve sleep and reduce inflammation in multiple myeloma patients after stem cell transplant

  A multi-site study will test whether exposure to circadian-friendly morning light helps multiple myeloma patients recover after autologous stem cell transplantation by improving sleep and reducing inflammation.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11384508

• Understanding how bone marrow fat cells influence multiple myeloma progression

  A patient-facing overview of a grant studying how fat cells in the bone marrow interact with multiple myeloma cells and affect disease behavior.

  NIH research Mainehealth · Portland, United States · NIH-11381214

• 3D tumor microenvironment platform to test immunotherapies for multiple myeloma

  A 3D, lab-grown model of multiple myeloma’s tumor environment is being developed to help test immunotherapies and new drug options.

  NIH research Northeastern University · Boston, United States · NIH-11381067

• AI-powered imaging to predict and monitor multiple myeloma

  A patient-friendly project uses artificial intelligence to read whole-body MRI scans and predict how multiple myeloma will behave, helping doctors tailor care.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11381000

• Epigenetic clues to MM risk differences in African Americans

  This grant looks at how epigenetic changes might explain why African American people have higher rates of multiple myeloma than European Americans, with a focus on 5hmC marks in tumor cells.

  NIH research University of Chicago · Chicago, United States · NIH-11376445

• In Vivo Engineering of BCMA CAR T Cells for Multiple Myeloma

  A new NIH grant aims to develop lipid nanoparticle systems that deliver BCMA CAR instructions directly to patients’ immune cells to treat multiple myeloma.

  NIH research Georgia Institute of Technology · Atlanta, United States · NIH-11367782

• BCMA CAR-T therapy with opaganib for ultrahigh risk multiple myeloma

  A first-in-human-style treatment using a patient’s own CAR-T cells plus a targeted drug to help people with very high-risk multiple myeloma live longer and better.

  NIH research University of Oklahoma Hlth Sciences Ctr · Oklahoma City, United States · NIH-11366573

• Movement is medicine in multiple myeloma: exercise-boosted immune and metabolic signals linked to treatment response

  A study will look at how exercise changes immune and metabolic markers in the bone marrow of people with multiple myeloma to see if these changes predict how well treatment works.

  NIH research Roswell Park Cancer Institute Corp · Buffalo, United States · NIH-11366341

• New targets on myeloma cells to drive smarter immunotherapies

  Researchers are seeking new cell surface targets on myeloma cells to develop better immunotherapies for people with multiple myeloma who have exhausted other treatments.

  NIH research H. Lee Moffitt Cancer Ctr & Res Inst · Tampa, United States · NIH-11365896

• Osteocytes and bone disease in Multiple Myeloma: targeting local FGF23 to slow cancer and improve bone health

  This grant explores whether blocking a bone-cell signal (FGF23) produced by osteocytes can slow multiple myeloma growth and reduce bone damage.

  NIH research Univ of Arkansas for Med Scis · Little Rock, United States · NIH-11359672

Related topics

Quick answers

How many Myeloma clinical trials are recruiting right now?

21, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 8 countries. The most sites are in United States (10 trials), Australia (4 trials), France (3 trials), Spain (2 trials), Canada (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 2/3: 4, Phase 1: 4. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →